Pharmaceuticals
Nutriband Files Provisional Patent to Strengthen AVERSA Abuse-Deterrent Technology Protection
Nutriband Inc. has filed a provisional patent application to expand protection for its AVERSA abuse-deterrent transdermal technology, potentially extending patent coverage by 20 years and strengthening the company's position in addressing prescription drug misuse.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
Nutriband Chairman to Present at Emerging Growth Conference, Highlighting Abuse-Deterrent Technology
Nutriband Inc. Chairman Serguei Melnik will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, showcasing the company's AVERSA abuse-deterrent technology for transdermal pharmaceutical products.
ABVC BioPharma Receives $566,000 in Cumulative Payments Under Vitargus Licensing Agreement
ABVC BioPharma has received cumulative payments of $566,000 from ForSeeCon Eye Corporation under their Vitargus licensing agreement, with the funds supporting GMP facility preparation for the biodegradable vitreous substitute's production.
Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.
Nightmare Bacteria Infections Surge in U.S., Prompting Urgent Response from Biotech Sector
The rapid spread of antibiotic-resistant 'nightmare bacteria' in the United States is driving increased focus on biotech companies developing novel treatments to address this growing public health crisis.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
Soligenix Secures $7.5 Million Financing to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, providing critical funding to advance multiple late-stage rare disease treatments including its cutaneous T-cell lymphoma therapy HyBryte™.
FDA Guidance Accelerates Lantern Pharma's Pediatric Brain Cancer Therapy Development
Lantern Pharma received FDA guidance that will help advance its LP-184/STAR-001 therapy for rare pediatric brain cancers toward clinical trials planned for 2026, representing significant progress in treating conditions with limited options.
Branded Legacy Subsidiary Files Provisional Patent for Innovative Intranasal Drug Delivery Platform
Branded Legacy's subsidiary BioLegacy Evaluative Group has filed a provisional patent for an air-powered intranasal drug delivery device that could revolutionize treatment for opioid overdoses and other conditions requiring precise nasal administration.
Quantum BioPharma Shareholders Approve Corporate Direction at Annual Meeting
Quantum BioPharma Ltd. secured full shareholder support for its strategic direction during its annual general meeting, highlighting investor confidence in the company's neurodegenerative and metabolic disorder treatments.
Annovis Bio Appoints Mark Guerin as CFO to Lead Financial Strategy During Critical Late-Stage Trials
Annovis Bio has appointed experienced financial executive Mark Guerin as Chief Financial Officer to guide the company's financial strategy as its lead drug candidate buntanetap advances through late-stage clinical trials for Alzheimer's and Parkinson's disease.
Nutriband to Present AVERSA Technology Strategy at MicroCap Rodeo Conference
Nutriband Inc.'s upcoming presentation at the MicroCap Rodeo Conference highlights the company's strategic direction for its innovative AVERSA abuse-deterrent technology platform, which addresses critical safety concerns in transdermal pharmaceutical delivery.
Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.
Stonegate Capital Partners Initiates Coverage on Medicus Pharma, Highlighting Strategic Pipeline Expansion
Investment firm Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd., emphasizing the company's strategic acquisitions and partnerships that position it for growth in dermatology and infectious disease treatments.
Soligenix Appoints Former White House Economic Advisor Tomas Philipson to Guide Rare Disease Drug Development
Soligenix's appointment of healthcare policy expert Tomas Philipson signals strategic positioning to navigate regulatory pathways for its lead rare disease treatment HyBryte™, potentially accelerating market access for unmet medical needs.
Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Oncotelic Therapeutics Advances Late-Stage Oncology Pipeline Under Proven Leadership
Oncotelic Therapeutics is progressing multiple late-stage clinical programs in high-unmet-need oncology indications under CEO Dr. Vuong Trieu, whose track record with blockbuster cancer drugs positions the company for potential therapeutic breakthroughs.
Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has obtained FDA approval for a Type C meeting regarding its AVERSA™ abuse-deterrent fentanyl patch technology, marking a significant regulatory milestone in addressing opioid abuse through transdermal pharmaceutical innovation.
Oncotelic Therapeutics Advances Cancer Research with AI and Nanomedicine Pipeline
Oncotelic Therapeutics is leveraging artificial intelligence and nanomedicine to develop innovative treatments for aggressive cancers and rare pediatric diseases, backed by a substantial intellectual property portfolio.
Oncotelic Therapeutics Advances RNA Therapy for High-Unmet-Need Cancers Amid Rising Global Cancer Burden
Oncotelic Therapeutics is developing innovative RNA-based treatments for underserved cancers, addressing the growing global cancer crisis with recently completed phase 1 clinical trials.
Oncotelic Therapeutics Advances Cancer and Rare Disease Treatments Through AI and Nanomedicine Innovations
Oncotelic Therapeutics is leveraging artificial intelligence, nanomedicine, and a robust intellectual property portfolio to develop transformative treatments for difficult cancers and rare pediatric diseases, positioning itself among leading innovators in biotechnology.
Clene's CNM-Au8 Shows Promise in Addressing Cellular Dysfunction in Parkinson's Disease
Clene Inc.'s investigational therapy CNM-Au8 demonstrates potential to improve mitochondrial health and reduce inflammation in Parkinson's disease models, offering new hope for addressing the underlying cellular mechanisms driving neurodegeneration.
Oncotelic Therapeutics Featured in Editorial Highlighting Innovative Cancer and Rare Disease Pipeline
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial underscores the company's growing prominence in developing RNA-based and immunotherapy treatments for aggressive cancers and pediatric rare diseases, positioning it for significant market growth.
Oncotelic Therapeutics Advances RNA-Based and Immunotherapy Pipeline to Address Unmet Medical Needs in Cancer and Rare Diseases
Oncotelic Therapeutics is leveraging AI and nanomedicine to develop breakthrough treatments for aggressive cancers and pediatric rare diseases, positioning the company alongside industry leaders in transforming biotech innovation.
Cybin Executives to Present at TD Cowen Neuropsychiatry Summit Amid Phase 3 Depression Treatment Development
Cybin Inc. executives will present at the TD Cowen Neuropsychiatry & Epilepsy Summit, highlighting the company's late-stage development of novel mental health treatments including CYB003, which has received FDA Breakthrough Therapy Designation for major depressive disorder.
Nutriband Secures $5.3 Million Through Warrant Exercises, Bolstering AVERSA™ Fentanyl Development
Nutriband Inc. raised $5.3 million through voluntary warrant exercises at $6.43 per share, demonstrating strong investor confidence in its abuse-deterrent transdermal patch technology AVERSA™ Fentanyl ahead of its FDA submission.
Nutriband Reports 51% Revenue Growth, Advances Abuse-Deterrent Fentanyl Patch Toward FDA Approval
Nutriband Inc. achieved significant revenue growth and strengthened its financial position to advance AVERSA Fentanyl, potentially becoming the first global abuse-deterrent transdermal fentanyl product with estimated peak annual sales of $80-200 million.